Form 4: Hologic Merger Completes, Executive Ownership Changes

Hologic, Inc. has completed its merger, resulting in significant changes to executive beneficial ownership of company securities.

Summary

• This filing reports changes in beneficial ownership for Jan Verstreken, Group President, International at Hologic Inc.
• The changes are a result of the completion of the merger between Hologic, Inc. and Hopper Parent Inc. (and its subsidiary Hopper Merger Sub Inc.) on April 7, 2026.
• As part of the merger, each share of Hologic common stock was converted into $76.00 in cash and one contingent value right (CVR) potentially worth up to $3.00.
• All outstanding stock options and performance stock units (PSUs) held by Mr. Verstreken were cancelled and converted into rights to receive the merger consideration.
• Specifically, options with an exercise price below $76.00 were converted into cash and CVRs. Options with an exercise price between $76.00 and $79.00 were converted into CVRs, with a net payment.
• Options with an exercise price at or above $79.00 were cancelled for no consideration.
• Performance stock units were deemed achieved at the greater of target or actual performance levels and cancelled, converting into the right to receive merger consideration.
• Following the merger, Mr. Verstreken no longer beneficially owns any shares of Hologic common stock directly or indirectly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting on the completion of a merger and the resulting changes in executive beneficial ownership, rather than new operational or financial performance.

Positives

• The merger consideration of $76.00 per share in cash provides immediate value to shareholders.
• The inclusion of a contingent value right (CVR) offers potential for additional upside up to $3.00 per share.
• Performance stock units were recognized based on achieved performance, ensuring executives are rewarded for results.
• Stock options with exercise prices below the cash consideration were converted into cash and CVRs, providing value to option holders.

Negatives

• Stock options with exercise prices at or above $79.00 were cancelled with no consideration received.
• The reporting person, Jan Verstreken, no longer holds any direct or indirect beneficial ownership of Hologic common stock post-merger.

Risks

• The value of the CVR is contingent and may not be fully realized, depending on future performance or events.
• Shareholders and option holders with higher exercise prices may not have received the full benefit of the merger consideration.

Future Outlook

The future outlook for Hologic, Inc. is now tied to the performance and payout of the contingent value rights (CVRs) and the strategic direction of the acquiring entity, Hopper Parent Inc.

Management Comments

• The merger was completed as per the Agreement and Plan of Merger dated October 21, 2025.
• Each share of Hologic common stock was converted into $76.00 in cash and a CVR for up to $3.00.
• Outstanding stock options and performance stock units were cancelled and converted into rights to receive merger consideration.
• Performance goals for PSUs were deemed achieved at the greater of target or actual levels.

Industry Context

StockSavvy.ai notes that the completion of this merger signifies a significant consolidation event in the medical technology sector, a trend driven by the pursuit of scale, innovation, and market share.

Stakeholder Impact

• Shareholders: Received $76.00 in cash per share plus a CVR, providing immediate liquidity and potential for further upside.
• Option Holders: Received cash and/or CVRs based on their option's exercise price relative to the merger consideration.
• PSU Holders: Received merger consideration based on achieved performance levels.
• Employees: Their future employment and compensation structures will be determined by the new parent company, Hopper Parent Inc.

Next Steps

• Shareholders and former option/PSU holders will receive the merger consideration as outlined.
• The contingent value rights (CVRs) will be subject to their own terms and conditions for potential future payouts.
• Hologic, Inc. will operate as a wholly owned subsidiary of Hopper Parent Inc.

Key Dates

Keywords

Hologic Inc, HOLX, Merger, Form 4, Beneficial Ownership, Stock Options, Performance Stock Units, Contingent Value Right, SEC Filing, Executive Compensation